Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients

• Status: Completed
• Trial end date: 2004-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Our main hypothesis is that inhalation of milrinone can reduce the elevated pulmonary arterial pressure due to severe mitral valve regurgitation without compromising systemic hemodynamics. Therefore, the effects of a brief inhaled milrinone (IH) on pulmonary artery pressure are determined and compared to those of intravenous milrinone (IV) in severe mitral regurgitation patients undergoing mitral valve surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Konkuk University Medical Center
• Treatments: Milrinone

Criteria

Inclusion Criteria:

• patients undergoing mitral valve surgery for chronic mitral regurgitation

• estimated pulmonary hypertension (systolic PAP > 50 mmHg estimated by the velocity of tricuspid valve regurgitation in preoperative transthoracic echocardiography)

• patients who agreed to participate in this study and signed written informed consent

Exclusion Criteria:

• preoperative supraventricular tachycardia (SVT),

• atrial fibrillation,

• atrial flutter,

• multiple ventricular ectopic contractions,

• continuous inotropic support,

• LV ejection fraction (EF) < 30%,

• emergent surgery,

• obstructive cardiomyopathy,

• bronchial asthma

• biochemical evidence of hepatic disease or renal impairment